Send to

Choose Destination
Open Med Chem J. 2011;5:31-9. doi: 10.2174/1874104501105010031. Epub 2011 Mar 9.

Structures, targets and recent approaches in anti-leishmanial drug discovery and development.

Author information

London School of Hygiene & Tropical Medicine, Keppel Street, London WC1E 7HT, UK.


Recent years have seen a significant improvement in available treatment options for leishmaniasis. Two new drugs, miltefosine and paromomycin, have been registered for the treatment of visceral leishmaniasis (VL) in India since 2002. Combination therapy is now explored in clinical trials as a new treatment approach for VL to reduce the length of treatment and potentially prevent selection of resistant parasites. However there is still a need for new drugs due to safety, resistance, stability and cost issues with existing therapies. The search for topical treatments for cutaneous leishmaniasis (CL) is ongoing. This review gives a brief overview of recent developments and approaches in anti-leishmanial drug discovery and development.


Leishmaniasis; drug development.; drug discovery

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center